APA (7th ed.) Citation

TL, S., KG, B., AJ, J., CL, C., CD, B., MC, H., & SC, M. (2024). Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal of surgical oncology, 130(1), 40. https://doi.org/10.1002/jso.27654

Chicago Style (17th ed.) Citation

TL, Sutton, Billingsley KG, Johnson AJ, Corless CL, Blanke CD, Heinrich MC, and Mayo SC. "Adjuvant Imatinib in High-risk Resected Gastrointestinal Stromal Tumors: Merely Delaying the Inevitable?" Journal of Surgical Oncology 130, no. 1 (2024): 40. https://doi.org/10.1002/jso.27654.

MLA (9th ed.) Citation

TL, Sutton, et al. "Adjuvant Imatinib in High-risk Resected Gastrointestinal Stromal Tumors: Merely Delaying the Inevitable?" Journal of Surgical Oncology, vol. 130, no. 1, 2024, p. 40, https://doi.org/10.1002/jso.27654.